Form 4: NSV Partners III LP Reports Distribution of Ventyx Biosciences Shares to Limited Partners

NSV Partners III LP reports a pro rata distribution of 695,339 common stock shares of Ventyx Biosciences to its limited partners on April 12, 2024, resulting in a decrease in direct ownership but maintaining significant indirect beneficial ownership.

Summary

• On April 12, 2024, NSV Partners III LP distributed 695,339 shares of Ventyx Biosciences common stock to its limited partners.
• The distribution was conducted on a pro rata basis and involved no consideration.
• Following the transaction, NSV Partners III LP directly owns zero shares but maintains indirect beneficial ownership of 7,744,296 shares.
• The indirectly held shares are owned through various entities including NSV Investments I, L.P., NSV Investments III, L.P., NSV Partners III, L.P., New Science Ventures, LLC, NSV Partners II, LLC, and NSV Investments II, L.P.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing a distribution of shares. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about a transaction.

Industry Context

Form 4 filings are standard disclosures required by the SEC when significant changes in beneficial ownership occur, providing transparency to the market regarding insider transactions.

Stakeholder Impact

• The distribution of shares to limited partners may have a minor impact on the shareholder base.
• The transaction does not appear to directly affect employees, customers, suppliers, or creditors.

Key Dates